Evidence map›Paper›PMID 41249612›Full record

ArticleInflammopharmacology2025

Targeting neuroinflammatory pathways in epilepsy: a combined network-pharmacology and in vivo study of dapagliflozin and ticagrelor.

Maanvi Dhureja, Anjana Munshi, Puneet Kumar

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Maanvi DhurejaDepartment of Pharmacology, Central University of Punjab, Bathinda, Punjab, India.
Anjana MunshiDepartment of Human Genetics and Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India.
Puneet KumarDepartment of Pharmacology, Central University of Punjab, Bathinda, Punjab, India. punnubansal79@gmail.com.ORCID http://orcid.org/0000-0002-7978-1043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesEpilepsy is a common neurological disorder that imposes a substantial socioeconomic burden. Today, drug repurposing has gained attention, allowing researchers to find new targets for existing therapies. Therefore, the present study aimed to evaluate the anticonvulsant actions of dapagliflozin and ticagrelor in maximal electroshock-induced convulsions in mice model of epilepsy.

methodsThe current study used two approaches, a computational and an experimental approach. The computational approach was used to identify the common targets between test drugs and epilepsy, to perform pathway enrichment analysis, and to find the binding efficiency between drugs and targets. Furthermore, experimental approach involves induction of seizures using a maximal electroshock (MES) convulsometer. Swiss albino mice were pre-treated with dapagliflozin (2.5 mg/kg & 5 mg/kg) and ticagrelor (50 mg/kg & 100 mg/kg) for 14 days. On day 15th, all the animals received maximum electroshock of 50 mA for 0.2 s via trans-auricular electrodes, and latency to generalised tonic-clonic seizures was observed. After 24 h, animals were euthanised, hippocampal region was isolated, and various molecular parameters, such as analysis of GABA content and GAD1 expression, immunohistochemistry of GFAP, and protein expression analysis of p- ERK1/2, p-TLR4, and p65 subunit of NF-κB, were performed.

resultsThe results of the computational approach suggested that MAPK, mainly ERK1/2, a possible target for dapagliflozin and ticagrelor, has been highly involved in the pathogenesis of epilepsy. These outcomes were further validated by an experimental approach, where MES-induced convulsions significantly raised the protein expression of p-ERK1/2, which impaired the GABA/GAD1 ratios. Furthermore, heightened p-ERK1/2 expression promotes the neuroinflammatory cascade, as evidenced by higher p-TLR4 and p65 subunit of NF-κB protein expression. The higher co-localisation of GFAP in hippocampal tissues indicated astrogliosis. However, dapagliflozin and ticagrelor significantly ameliorated these alterations, indicating both drugs possess anticonvulsant activity.

Indexed as

AnticonvulsantsBenzhydryl CompoundsEpilepsyGlucosidesNeuroinflammatory DiseasesTicagrelorAnimalsDisease Models, AnimalElectroshockHippocampusMaleMiceNetwork PharmacologySeizuresAnticonvulsantsBenzhydryl CompoundsdapagliflozinGlucosidesTicagrelorConvulsometerDapagliflozinEpilepsyNeuroinflammationSystem pharmacologyTicagrelor

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.